Vaccinex (NASDAQ: VCNX) is a clinical stage biotechnology company pioneering a differentiated approach to treating cancer and progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The Company’s lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers damaging inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer’s Disease, with ongoing exploration of potential Phase 3 development in Huntington’s disease. The Company has also developed a proprietary drug discovery platform, ActivMAb®, that it is leveraging thru strategic collaborations, particularly by exploiting its unique capability to select high value antibodies against important multi-pass membrane receptors.
Company Details
- Employees
- 29
- Address
- 1895 Mt Hope Ave, Rochester,new York 14620,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.vaccinex.com/
- Keywords
- of medicine.
- HQ
- Rochester, New York
Vaccinex Questions
Vaccinex's website is http://www.vaccinex.com/
Vaccinex's LinkedIn profile is https://www.linkedin.com/company/vaccinex
Vaccinex has
29 employees.
View email and phone details for 29
employees at Vaccinex.
Vaccinex's industry is
Biotechnology Research
Vaccinex's top competitors are
Oyagen Inc.,
Abtherx,
Stoke Therapeutics,
Single Cell Technology Inc.,
Transcode Therapeutics, Inc.,
Avantgen,
Fibrogen, Inc.,
Apogee Therapeutics,
Society For Immunotherapy Of Cancer (Sitc),
Ablexis, Llc.
Vaccinex's categories are Biotechnology Research
